|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-2-20
|
|
pubmed:abstractText |
Short-term administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, statins, has been shown to attenuate ischemia-reperfusion injury. However, the effects of long-term administration of statins on left ventricular (LV) remodeling and failure after myocardial infarction remain unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Monounsaturated,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA...,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinases,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase Type III,
http://linkedlifedata.com/resource/pubmed/chemical/Nos3 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Peptidyl-Dipeptidase A,
http://linkedlifedata.com/resource/pubmed/chemical/fluvastatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
19
|
|
pubmed:volume |
105
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
868-73
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11854129-Administration, Oral,
pubmed-meshheading:11854129-Animals,
pubmed-meshheading:11854129-Blotting, Western,
pubmed-meshheading:11854129-Body Weight,
pubmed-meshheading:11854129-Dilatation, Pathologic,
pubmed-meshheading:11854129-Disease Models, Animal,
pubmed-meshheading:11854129-Echocardiography,
pubmed-meshheading:11854129-Fatty Acids, Monounsaturated,
pubmed-meshheading:11854129-Heart Failure,
pubmed-meshheading:11854129-Hemodynamics,
pubmed-meshheading:11854129-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:11854129-Indoles,
pubmed-meshheading:11854129-Lung,
pubmed-meshheading:11854129-Male,
pubmed-meshheading:11854129-Matrix Metalloproteinases,
pubmed-meshheading:11854129-Mice,
pubmed-meshheading:11854129-Myocardial Infarction,
pubmed-meshheading:11854129-Myocardium,
pubmed-meshheading:11854129-Nitric Oxide Synthase,
pubmed-meshheading:11854129-Nitric Oxide Synthase Type II,
pubmed-meshheading:11854129-Nitric Oxide Synthase Type III,
pubmed-meshheading:11854129-Organ Size,
pubmed-meshheading:11854129-Peptidyl-Dipeptidase A,
pubmed-meshheading:11854129-Survival Rate,
pubmed-meshheading:11854129-Ventricular Function, Left,
pubmed-meshheading:11854129-Ventricular Remodeling
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
|
|
pubmed:affiliation |
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
